Is pomalidomide a targeted drug?

Pomalidomide (Pomalidomide) is an oral immunomodulatory drug, a new generation of thiazole riboside analogs, mainly used to treat multiple myeloma (MM) and certain hematological malignancies. Strictly speaking, pomalidomide is not a typical "targeted drug" that directly acts on specific gene mutations or molecular targets like tyrosine kinase inhibitors or monoclonal antibodies. Its mechanism of action is more complex, with multi-target regulatory properties, and it exerts anti-cancer effects through immune regulation, anti-angiogenesis and direct inhibition of tumor cell proliferation.

Specifically, pomalidomide can enhance the activity of T cells and natural killer (NK) cells in the body and improve the anti-tumor immune response. At the same time, it can regulate the tumor microenvironment and inhibit myeloma cell-dependent cytokine signaling, such as IL-6 and TNF-α, thereby blocking tumor cell growth and survival. Pomalidomide can also limit nutrient supply by affecting tumor-associated angiogenesis, further inhibiting tumor progression. Because these mechanisms are relatively broad, it is classified as an immunomodulator rather than a strictly targeted agent.

In clinical applications, pomalidomide is often used in combination with low-dose dexamethasone or other chemotherapy drugs to improve the therapeutic effect and prolong the progression-free survival of patients with multiple myeloma. Although it does not belong to traditional targeted drugs, its regulatory effect on specific immune and microenvironmental pathways can achieve "precision" therapeutic effects in clinical practice. Overseas studies have shown that pomalidomide shows significant efficacy in patients with relapsed or refractory multiple myeloma, and its immunomodulatory properties make it valuable in combination drug regimens.

In general, although pomalidomide is not a typical targeted drug, its multi-target immunomodulatory effect gives it a unique position in the treatment of hematological tumors.

Reference materials:https://en.wikipedia.org/wiki/Pomalidomide